Development and Validation of Novel FTIR Method for Quantitative Estimation of Silodosin in Bulk and Pharmaceutical Dosage Forms

Abstract

Silodosin was quantified in both pure and pharmaceutical dosage forms using a novel Fourier transform infrared (FTIR) spectroscopic technique. Silodosin is an alphablocker that works by relaxing the bladder and prostate muscles to alleviate benign prostatic hyperplasia symptoms. After baseline correction, the infrared spectrum revealed a variety of peaks, including intense, distinct peaks at 1620 cm-1 (C=O), 3201.61 cm-1 (NH), and 3384.84 cm-1 (OH). The method met the majority of validation requirements in the 40–200 g/mg range, with a coefficient of determination of 0.998, obtained using a simple calibration model. While FTIR methods are less complex, less expensive, and faster than other methods, they can be used to estimate silodosin in a variety of dose forms. Key words: FTIR, Infrared spectrum, baseline correction, validation.